(+)-[(18)F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls

PURPOSES: We present the first in-human brain PET imaging data of the new α4β2 nicotinic acetylcholine receptor (nAChR)–targeting radioligand (+)-[(18)F]Flubatine. Aims were to develop a kinetic modeling-based approach to quantify (+)-[(18)F]Flubatine and compare the data of healthy controls (HCs) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiepolt, Solveig, Becker, Georg-Alexander, Wilke, Stephan, Cecchin, Diego, Rullmann, Michael, Meyer, Philipp M., Barthel, Henryk, Hesse, Swen, Patt, Marianne, Luthardt, Julia, Wagenknecht, Gudrun, Sattler, Bernhard, Deuther-Conrad, Winnie, Ludwig, Friedrich-Alexander, Fischer, Steffen, Gertz, Hermann-Josef, Smits, René, Hoepping, Alexander, Steinbach, Jörg, Brust, Peter, Sabri, Osama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036219/
https://www.ncbi.nlm.nih.gov/pubmed/32935187
http://dx.doi.org/10.1007/s00259-020-05029-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036219/
https://www.ncbi.nlm.nih.gov/pubmed/32935187
http://dx.doi.org/10.1007/s00259-020-05029-w

Ejemplares similares